EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Paroxysmal nocturnal haemoglobinuria in pregnancy–a systematic review with meta analysis

James E Manning, Etienne Ciantar, Morag Griffin, Richard J Kelly

Annals of Hematology · 2025-04 · 104 (4) · 2517-2525

DOI: 10.1007/s00277-025-06353-7 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Annals of Hematology, online erschienen am 17.04.2025. Verfasst von James E Manning und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Haematology, Imperial College London, London, UK. j.manning@imperial.ac.uk. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal, Antibodies, Monoclonal, Humanized, Pregnancy Complications, Hematologic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The co-occurrence of Paroxysmal nocturnal haemoglobinuria (PNH) and pregnancy has traditionally been associated with poor feto-maternal outcomes. Eculizumab, a terminal complement inhibitor, is often used in pregnant patients, but the drug is not universally available. We therefore present the first systematic review with meta-analysis of outcomes in 190 pregnancies from 135 PNH patients, comparing those receiving eculizumab and those not. We searched PubMed for studies reporting on pregnancy outcomes in PNH. Thirty-five papers were selected for inclusion, the majority of which were case studies or small series. Eculizumab was used in 131 pregnancies. There was one maternal death reported in a woman who did not receive eculizumab. A higher rate of fetal survival was observed in pregnancies where eculizumab was used (82%) than those when it was not (69%). Miscarriage (< 24 weeks gestation) occurred twice as often in women not receiving eculizumab. Intrauterine death (≥24 weeks gestation), maternal thrombosis, bleeding (both antepartum and postpartum), and pre-eclampsia were over-represented in PNH pregnancies but did not significantly differ between treatment groups. Premature birth (< 37 weeks’ gestation) was observed in 32% of eculizumab pregnancies and 44% of non-eculizumab pregnancies. We conclude that Eculizumab appears to be safe and benefits pregnant women with PNH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemoglobinuria, ParoxysmalAntibodies, Monoclonal, HumanizedPregnancy Complications, HematologicHumansPregnancyFemalePregnancy OutcomeComplement Inactivating AgentsAbortion, Spontaneous

Stichwörter der Autor:innen

EculizumabParoxysmal nocturnal haemoglobinuriaPnhPregnancy

Substanzen

eculizumabAntibodies, Monoclonal, HumanizedComplement Inactivating Agents

Autor:innen und Institutionen

  • Centre for Haematology, Imperial College London, London, UK. j.manning@imperial.ac.uk.
  • Department of Haematology, Imperial College Healthcare NHS Trust, London, UK. j.manning@imperial.ac.uk.
  • Department of Obstetrics, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Zitieren

APA

Manning, J. E., Ciantar, E., Griffin, M., & Kelly, R. J. (2025). Paroxysmal nocturnal haemoglobinuria in pregnancy–a systematic review with meta analysis. Annals of Hematology, 104(4), 2517-2525. https://doi.org/10.1007/s00277-025-06353-7

Vancouver

Manning JE, Ciantar E, Griffin M, Kelly RJ. Paroxysmal nocturnal haemoglobinuria in pregnancy–a systematic review with meta analysis. Annals of Hematology. 2025;104(4):2517-2525. doi:10.1007/s00277-025-06353-7

BibTeX
@article{Manning2025,
  author = {Manning, James E and Ciantar, Etienne and Griffin, Morag and Kelly, Richard J},
  title = {Paroxysmal nocturnal haemoglobinuria in pregnancy–a systematic review with meta analysis},
  journal = {Annals of Hematology},
  year = {2025},
  volume = {104},
  number = {4},
  pages = {2517--2525},
  doi = {10.1007/s00277-025-06353-7}
}
Kostenlos starten →